海外研报

GS--EASD Day 1 takeaways - long acting insulin

The key focus areas for day 1 of EASD were the (1) updated data for the weeklyinsulin therapies from Novo Nordisk and Eli Lilly (covered by Chris Shibutani), (2)

GS--Global Markets Daily: Q&A on the Dollar After the First Cut

Q: Does it matter how much the Fed cuts versus other G10 central banks ineach cycle?

GS--GS China+ Conference 2024 – Key Takeaways: Cyclical inflection in producers’ eyes,

We hosted a panel on producers’ feedback on China capacity (link). The feedbackreaffirmed our assessment of 1) industry supply response in the electric vehicle,

JPM--US MARKET INTELLIGENCE ELECTION UPDATE

WHAT HAS CHANGED: The key changes since our last publication was last night's debate, across-asset call with our Research teams, including Federal Government Relations, and the

EF--Mixed jobs report offers no definitive signal for the Fed 01

The August employment report was a decidedly mixed one, improving compared to July but by less than anticipated for some metrics. On

ECB --September 2024 Meeting Preview

We expect a 25bp cut, in line with market pricing. The language in the statement is unlikely to change

MS_Charts That Caught My Eye_20240910

A guiding principle at Morgan Stanley Research is to enhance your investment process by delivering unique insights that

GS--Slowing growth with downside risks That is our outlook for the world's

At EASD today, Novo presented data for its oral amycretin drug (GLP-1/amylinco-agonist in a single molecule). The data for weight loss was already previously

SocGen - FX Pulse - Weekly FX summary – 9 September

US CPI on Wednesday. Presidential debate between candidates Trump/Harris on Tuesday. ECB f/c to cut 25bp on

SocGen - Market Wrap-up - New issue premiums are not that low

New issue volumes have been very strong and have been taken down quickly by a highly receptive market. However, the higher new issue premiums are a nice